PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT
May 1, 2008, 00:00
10.1016/S1098-3015(10)70618-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)70618-5/fulltext
Title :
PCV30 CLOPIDOGREL IS COST-EFFECTIVE COMPARED WITH ASPIRIN IN UNITED KINGDOM PATIENTS WITH A MYOCARDIAL INFARCTION WHO SUBSEQUENTLY SUSTAIN AN ISCHAEMIC STROKE OR PERIPHERAL ARTERIAL DISEASE EVENT
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70618-5&doi=10.1016/S1098-3015(10)70618-5
First page :
Section Title :
Open access? :
No
Section Order :
347